Perioperative nivolumab in intermediate/high risk kidney cancer patients
The standard of care for patients with intermediate/high risk kidney [...]
Factors affecting outcomes after nephrectomy for metastatic kidney cancer
Nephrectomy is surgery to remove all or part of a [...]
Does neoadjuvant therapy improve outcomes in localised kidney cancer?
At the 2023 Society of Urologic Oncology (SUO) Annual Meeting, [...]
ESMO 2022: Nivolumab before and after surgery to prevent recurrence of kidney cancer
In this phase 3 randomised study, presented at the European [...]
Delayed nephrectomy after immunotherapy for metastatic kidney cancer
Neoadjuvant therapy is the treatment given as a first step [...]
Neoadjuvant axitinib may enable partial nephrectomy of complex kidney tumours
Just over half of the patients from a phase 2 [...]
ASCO GU 2022: Neoadjuvant cabozantinib clinically active in kidney cancer
Results from a phase 2 study were presented at the [...]
ASCO GU 2022: Neoadjuvant avelumab/axitinib shows promise in kidney cancer
Results from the NeoAvAx clinical trial were presented at the [...]
International Kidney Cancer Symposium (IKCS) 2021
The International Kidney Cancer Symposium (IKCS) 2021 took place in [...]
Neoadjuvant nivolumab for patients with non-metastatic high risk kidney cancer
A recent phase 1 trial showed that treatment with nivolumab [...]
